Neose Technologies (NTEC) to Hold Q4 2007 Earnings Conference Call March 10

Neose Technolgies (NASDAQ:NTEC) will hold a conference call on Monday March 10 at 5:00 pm to discuss the fourth quarter earnings for 2007.
Neose Technologies, a biopharmaceutical company, is engaged in the development of therapeutic proteins.  The company’s primary candidates are GlycoPEG-EPO (NE-180) and GlycoPEG-GCSF.  NE 180 is produced in inset cells as a long lasting form of erythropoietin.  NE-180 completed a Phase I clinical trial during the year ended December 31, 2006.  The company received approval from Swissmedic, in January 2007, to initiate a Phase II human trial for safety, tolerability and dose response evaluation in cancer patients who receive platinum based chemotherapy.

The company received approval from the United States Food and Drug Administration in March 2007 to initiate clinical trails for its amended investigational new drug application.

GlycoPEG-GCSF, a long acting form of granulocyte colony stimulating factor (G-CSF) is co-developing with BioGeneriX AG.

For more Conference Call related events or to post your own events, visit:

http://events.finditt.com/Events_List.aspx?catid=12